Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. - Wikidata - awgldk - TriplyDB

Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice.

Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice.

http://www.wikidata.org/entity/Q55032942

about

Identification of protein kinase D2 as a pivotal regulator of endothelial cell proliferation, migration, and angiogenesis Nicotine and pathological angiogenesis Exercise increases endostatin in circulation of healthy volunteers Therapeutic angiogenesis for cardiovascular disease Protein Kinase D1 Signaling in Angiogenic Gene Expression and VEGF-Mediated Angiogenesis Nuclear Molecular Imaging for Vulnerable Atherosclerotic Plaques Quantifying progression and regression of thrombotic risk in experimental atherosclerosis Molecular Imaging of Vulnerable Atherosclerotic Plaques in Animal Models.The Role of CC-Chemokines in the Regulation of Angiogenesis New Insights Into Tobacco-Induced Vascular Disease: Clinical Ramifications Regulation of VEGF-induced endothelial cell PAF synthesis: role of p42/44 MAPK, p38 MAPK and PI3K pathways Perspectives and opportunities for nanomedicine in the management of atherosclerosis.Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.Normalization of the vasculature for treatment of cancer and other diseases.Perfluorocarbon nanoemulsions for quantitative molecular imaging and targeted therapeutics.Clinical applications of perfluorocarbon nanoparticles for molecular imaging and targeted therapeutics.Multiple imputation and analysis for high-dimensional incomplete proteomics data Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes.Novel role of NADPH oxidase in angiogenesis and stem/progenitor cell function.The vasa vasorum in diseased and nondiseased arteries Mechanisms of nucleotide trafficking during siRNA delivery to endothelial cells using perfluorocarbon nanoemulsions.VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial Therapeutic angiogenesis in diabetes and hypercholesterolemia: influence of oxidative stress.Circulating angiopoietins-1 and -2, angiopoietin receptor Tie-2 and vascular endothelial growth factor-A as biomarkers of acute myocardial infarction: a prospective nested case-control study Apoptosis in the vasculature: mechanisms and functional importance.The extracellular matrix can regulate vascular cell migration, proliferation, and survival: relationships to vascular disease.Therapeutic angiogenesis: theoretic problems using vascular endothelial growth factor.Anti-inflammatories for cardiovascular disease Determination of the disulfide bond pattern of the endogenous and recombinant angiogenesis inhibitor endostatin by mass spectrometry.The acute phase reactant response to respiratory infection with Chlamydia pneumoniae: implications for the pathogenesis of atherosclerosis Akt pathway is hypoactivated by synergistic actions of diabetes mellitus and hypercholesterolemia resulting in advanced coronary artery disease.Plaque angiogenesis and atherosclerosis.Atherosclerosis and plaque rupture.Prevention of vasa vasorum neovascularization attenuates early neointima formation in experimental hypercholesterolemia.Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (FGF-2)A novel poly-naphthol compound ST104P suppresses angiogenesis by attenuating matrix metalloproteinase-2 expression in endothelial cells.Assessment of neovascularization within carotid plaques in patients with ischemic stroke Low vasa vasorum densities correlate with inflammation and subintimal thickening: potential role in location--determination of atherogenesis Moderate hypoxia potentiates interleukin-1β production in activated human macrophages.Genetic targeting for cardiovascular therapeutics: are we near the summit or just beginning the climb?

P2860

Q24313566-2CD67E68-1CE5-45EF-B353-32B4AA67408A Q24606748-26F88BC3-CC9E-4402-A2DF-4CA2103FFC9C Q24791729-7504E7EC-5CC6-41EA-BAB3-B3B6415D7239 Q24799337-2528A20E-B202-4106-A1EE-4F0AA0883984 Q26747243-7C1AD7B0-2AEE-488C-9D04-9898831BE8D2 Q26781838-0E3DF5B1-FAC6-4988-A35B-63A1A0323996 Q27318779-B8BCB769-BEFF-4AE9-BAFD-DAA112F52557 Q28070313-491C003B-5384-4277-AE7F-3BB69D43693B Q28077024-8E2C4124-8E38-4E8F-AAF5-3450E0169770 Q28088290-FDC404DA-FBFE-404F-BD39-400E3B4C5413 Q28363743-5E85E510-FF76-4D77-9572-68C783CEDD92 Q30455490-C6A55288-8E86-47FF-85CE-6FE5817DB8C8 Q30469815-C491620E-C0D5-46EA-83F6-3086D515B7D5 Q30471456-0D948497-219F-4D12-9579-6BF3D05B2EFB Q30486235-6C2F74BD-AD41-4F0E-B3CB-7FAEFD162B94 Q30489686-8F261113-0735-4482-A80B-A7F72C90D1EB Q31023015-ABF13318-9DDA-4A4A-9D87-46FBDA63EE6D Q31124912-18139626-43AA-438F-9ACB-EFCD4F7D322C Q33649852-676FC942-9BED-4B78-832C-9090B6BC8C43 Q33656008-D0885E8C-FBB6-44EF-B3E4-01CD4B848A09 Q33684461-3A2898BB-4358-482F-98E4-A9DD4A87A802 Q33713721-F2C9E81B-9F48-4761-9E60-039BE2294A22 Q33765479-CC153CAC-F1C7-4E77-8F6E-477BBC56F954 Q33932129-83A33416-1C61-4A1D-9421-6AC20B5773E3 Q33959479-EB7B43DD-D1D9-483A-8517-459CD5C16146 Q34022649-48CC1C3C-E5C8-4C41-A2F5-9514A71913BC Q34027378-943D0C46-7BA1-4C26-8990-77BA08F91813 Q34073512-9E7A3F81-D285-4EAD-9197-31B5C99796B4 Q34083540-40E548E5-A015-461C-AA4E-996104FA68C1 Q34140532-F45B2685-9C93-4463-A281-41AE5F755C4C Q34150587-0BECCF18-A6EB-424A-9B46-B4743577CD0A Q34207424-21D2A3BA-F6FA-4B72-BF2E-243946DC94D9 Q34236205-BE8E1D1B-1834-4620-869D-2F06470416A4 Q34296762-62A35381-439F-493F-AE54-8E48370F80B4 Q34312563-69C140E7-63CE-4B5C-AA55-341BC2F9D2BF Q34358400-FAE98124-84B1-48D4-AD43-CA08CA6A647C Q34389842-76288CBB-EA51-46D9-B781-3A7316833625 Q34400309-4E324B5E-B1CD-4C8E-A448-2B03D022972B Q34403101-D280904C-187A-415A-8FDE-69EAFEA4C825 Q34482530-9797E1D3-2B5C-49BE-A48E-B32A03BD2EF2

P2860

Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice.

http://www.wikidata.org/entity/Q55032942

description

1999 nî lūn-bûn

@nan

1999年の論文

@ja

1999年学术文章

@wuu

1999年学术文章

@zh

1999年学术文章

@zh-cn

1999年学术文章

@zh-hans

1999年学术文章

@zh-my

1999年学术文章

@zh-sg

1999年學術文章

@yue

1999年學術文章

@zh-hant

name

Angiogenesis inhibitors endost ...... olipoprotein E-deficient mice.

@en

Angiogenesis inhibitors endost ...... olipoprotein E-deficient mice.

@nl

type

label

Angiogenesis inhibitors endost ...... olipoprotein E-deficient mice.

@en

Angiogenesis inhibitors endost ...... olipoprotein E-deficient mice.

@nl

prefLabel

Angiogenesis inhibitors endost ...... olipoprotein E-deficient mice.

@en

Angiogenesis inhibitors endost ...... olipoprotein E-deficient mice.

@nl

P1433

Q55032942-19F88C01-B5B7-42E4-97C8-21101083BE39

P1476

Q55032942-78C5ABF2-A56F-462B-BE14-C5EA812A20C0

P2093

Q55032942-37120EE1-D950-433E-9645-C4ADBEC57E39

Q55032942-4267C86E-7914-4430-BE4D-835B4776F87F

Q55032942-9CCC2218-5049-4EA4-8F81-8CB44AF94FA5

Q55032942-A681CF38-D800-4000-8246-E0289D5C8413

Q55032942-CBA07A81-3320-4E4A-A309-22F3DE734983

Q55032942-D1D2D3A9-2A00-4A73-8C5E-D5C340FA6F2D

P304

Q55032942-489F419F-D4A1-491D-938B-151648BCE2C0

P31

Q55032942-B091FB3C-D549-40D7-B648-1B185AD9EEB4

P356

Q55032942-65E3E6EC-6B75-425B-841F-C3504C53E748

P407

Q55032942-0A7EF873-B23C-4B09-9A7C-7061D774FF5D

P433

Q55032942-65D7A145-17E3-4525-8631-18E3B6EC271B

P478

Q55032942-84A10012-5B77-46F0-81C5-486FBBBBB901

P577

Q55032942-F03F6CAA-2824-406A-92B0-9826D0EBEA9C

P5875

Q55032942-004B38A0-1A47-4998-9F2D-7D7572147F88

P698

Q55032942-64EC4AFA-F9BE-49D3-81FD-36D65D195CBE

P921

Q55032942-4DC6CD35-D220-4A1E-8968-43FB2983F5CF

P356

01.CIR.99.13.1726

P1433

P1476

Angiogenesis inhibitors endost ...... olipoprotein E-deficient mice.

@en

P2093

E Flynn

http://www.w3.org/2001/XMLSchema#string

E Heller

http://www.w3.org/2001/XMLSchema#string

J Folkman

http://www.w3.org/2001/XMLSchema#string

K S Moulton

http://www.w3.org/2001/XMLSchema#string

M A Konerding

http://www.w3.org/2001/XMLSchema#string

W Palinski

http://www.w3.org/2001/XMLSchema#string

P304

1726-1732

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/01.CIR.99.13.1726

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P577

1999-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13107046

http://www.w3.org/2001/XMLSchema#string

P698

10190883

http://www.w3.org/2001/XMLSchema#string

P921

neovascularization